drugset / Trial / NCT05604261
A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux Esophagitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2, randomized, double-blind, double-dummy, positive drug parallel controlled, multicenter trial to evaluate efficacy and safety of within 8 weeks (including 8 weeks) treatment of Anaprazole 40mg QD, 60mg QD compared with Rabeprazole 20mg QD in patients with reflux esophagitis.
Timeline
- Start
- 2022-12
- Primary completion
- 2023-07
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anaprazole | Other / unclassified | 40 mg | Oral |
| Subject | Anaprazole | Other / unclassified | 60 mg | Oral |
| Comparator | Rabeprazole | Small molecule | 20 mg | Oral |